Natural killer (NK) cells, the large granular lymphocytes differentiated from the common
lymphoid progenitors, were discovered in early 1970's. They are members of innate …

The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

Cytokines are major drivers of autoimmunity, and biologic agents targeting cytokines have
revolutionized the treatment of immune-mediated diseases. Despite the effectiveness of …

Myasthenia gravis (MG) is an autoimmune antibody-mediated disorder of neuromuscular
synaptic transmission. The clinical hallmark of MG consists of fluctuating fatigability and …

Background Multiple sclerosis (MS) is a chronic and autoimmune disease of the central
nervous system (CNS), mainly characterized by inflammatory demyelination, which …

Surgical resection remains the mainstay treatment for solid cancers, especially for localized
disease. However, the postoperative immunosuppression provides a window for cancer cell …

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous
system (CNS). It predominantly affects young women and is one of the most common causes …

Background Immunotherapy initiated early after first presentation of relapsing-remitting
multiple sclerosis is associated with improved long-term outcomes. One can therefore …

The treatment landscape for relapsing forms of multiple sclerosis (RMS) has expanded
considerably over the last 10 years with the approval of multiple new disease-modifying …